BlackRock
PDSB icon

BlackRock’s PDS Biotechnology PDSB Stock Holding History

BlackRock’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$335K Buy
554,048
+31,837
+6% +$24K ﹤0.01% 4625
2025
Q4 		$402K Buy
522,211
+4,692
+0.9% +$4.23K ﹤0.01% 4537
2025
Q3 		$523K Buy
517,519
+3,128
+0.6% +$3.68K ﹤0.01% 4445
2025
Q2 		$684K Buy
514,391
+26,358
+5% +$35.8K ﹤0.01% 4368
2025
Q1 		$581K Sell
488,033
-35,109
-7% -$49.9K ﹤0.01% 4359
2024
Q4 		$853K Buy
523,142
+34,846
+7% +$92.2K ﹤0.01% 4261
2024
Q3 		$1.87M Buy
488,296
+1,329
+0.3% +$4.43K ﹤0.01% 4021
2024
Q2 		$1.43M Sell
486,967
-1,380,460
-74% -$4.42M ﹤0.01% 4072
2024
Q1 		$7.4M Sell
1,867,427
-14,011
-0.7% -$72.2K ﹤0.01% 3509
2023
Q4 		$9.35M Buy
1,881,438
+77,955
+4% +$388K ﹤0.01% 3431
2023
Q3 		$9.11M Buy
1,803,483
+70,565
+4% +$387K ﹤0.01% 3388
2023
Q2 		$8.72M Buy
1,732,918
+1,272,801
+277% +$8.34M ﹤0.01% 3476
2023
Q1 		$2.83M Buy
460,117
+7,750
+2% +$63.4K ﹤0.01% 3886
2022
Q4 		$5.97M Sell
452,367
-18,332
-4% -$129K ﹤0.01% 3651
2022
Q3 		$1.4M Sell
470,699
-1,387
-0.3% -$5.89K ﹤0.01% 4354
2022
Q2 		$1.72M Buy
472,086
+36,482
+8% +$173K ﹤0.01% 4311
2022
Q1 		$2.7M Buy
435,604
+4,199
+1% +$26.1K ﹤0.01% 4268
2021
Q4 		$3.5M Buy
431,405
+2,227
+0.5% +$24K ﹤0.01% 4153
2021
Q3 		$6.4M Buy
429,178
+27,756
+7% +$346K ﹤0.01% 3862
2021
Q2 		$5.04M Buy
401,422
+358,623
+838% +$2.8M ﹤0.01% 3874
2021
Q1 		$194K Sell
42,799
-61,616
-59% -$248K ﹤0.01% 4746
2020
Q4 		$224K Hold
104,415
– – ﹤0.01% 4466
2020
Q3 		$244K Buy
104,415
+90,002
+624% +$252K ﹤0.01% 4376
2020
Q2 		$29K Hold
14,413
– – ﹤0.01% 4643
2020
Q1 		$10K Hold
14,413
– – ﹤0.01% 4714
2019
Q4 		$38K Hold
14,413
– – ﹤0.01% 4573
2019
Q3 		$49K Hold
14,413
– – ﹤0.01% 4538
2019
Q2 		$87K Sell
14,413
-2,388
-14% -$15.6K ﹤0.01% 4492
2019
Q1 		$124K Sell
16,801
-147
-0.9% -$1.23K ﹤0.01% 4342
2018
Q4 		$109K Sell
16,948
-19
-0.1% -$252 ﹤0.01% 4343
2018
Q3 		$279K Buy
16,967
+113
+0.7% +$2.03K ﹤0.01% 4255
2018
Q2 		$347K Sell
16,854
-42,020
-71% -$877K ﹤0.01% 4189
2018
Q1 		$1.39M Buy
58,874
+11,582
+24% +$3.11M ﹤0.01% 3788
2017
Q4 		$8.86M Buy
47,292
+592
+1% +$119K ﹤0.01% 3201
2017
Q3 		$10M Buy
46,700
+2,106
+5% +$435K ﹤0.01% 3175
2017
Q2 		$9.15M Buy
44,594
+7,827
+21% +$1.54M ﹤0.01% 3222
2017
Q1 		$6.7M Buy
36,767
+36,668
+37,038% +$7.26M ﹤0.01% 3282
2016
Q4 		$25K Sell
99
-219
-69% -$49.8K ﹤0.01% 3189
2016
Q3 		$66K Hold
318
– – ﹤0.01% 2832
2016
Q2 		$64K Buy
318
+312
+5,200% +$55.1K ﹤0.01% 2809
2016
Q1 		$1K Buy
+6
New +$1.07K ﹤0.01% 3548

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock's PDSB Position: Q1 2026 in Review

BlackRock increased its PDS Biotechnology (PDSB) stake by 6.1% in Q1 2026, buying an estimated $24K and bringing the position to 554,048 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #4625.

BlackRock first reported a position in PDSB in Q1 2016 and has held it in 41 quarters since. The position peaked at $10M in Q3 2017. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • BlackRock held 554,048 shares of PDS Biotechnology worth $335K as of Q1 2026.
  • BlackRock bought 31,837 PDS Biotechnology shares in Q1 2026, an estimated $24K.
  • PDS Biotechnology made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4625 holding.
  • BlackRock first reported a position in PDS Biotechnology in Q1 2016 and has held it in 41 quarters since.
  • BlackRock's PDS Biotechnology position peaked at $10M in Q3 2017.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.